Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy. Since monotherapy in cancer is generally not providing long-lasting clinical responses, we here...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Van Goethem, Alan, Yigit, Nurten, Moreno-Smith, Myrthala, Vasudevan, Sanjeev A., Barbieri, Eveline, Speleman, Frank, Shohet, Jason, Vandesompele, Jo, Van Maerken, Tom
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593624/
https://ncbi.nlm.nih.gov/pubmed/28915653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18982
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares